Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer

Oncotarget

Volumn 6, Issue 5, 2015, Pages 3136-3146

  Kirk, Jason S ^a   Schaarschuch, Kevin ^b   Dalimov, Zafardjan ^a   Lasorsa, Elena ^a   Ku, Sheng Yu ^a   Ramakrishnan, Swathi ^a   Hu, Qiang ^a   Azabdaftari, Gissou ^a   Wang, Jianmin ^a   Pili, Roberto ^a   Ellis, Leigh ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Epigenetics; Etoposide; Ezh2; Prostate cancer; Therapy; Top2a

Indexed keywords

ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); DZNEP; ETOPOSIDE; GSK 126; MESSENGER RNA; TOPOISOMERASE IIA; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; EZH2 PROTEIN, HUMAN; GSK126; GYRASE INHIBITOR; INDOLE DERIVATIVE; POLYCOMB REPRESSIVE COMPLEX 2; PYRIDONE DERIVATIVE; TUMOR ANTIGEN; TUMOR MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL DEATH; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE STRANDED DNA BREAK; DRUG CYTOTOXICITY; DRUG EFFICACY; EPIGENETICS; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; PROSTATE CANCER; PROSTATE CANCER CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DISEASE FREE SURVIVAL; DRUG SCREENING; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; PATHOLOGY; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PROSTATIC NEOPLASMS; TIME FACTOR; TUMOR CELL LINE; UPREGULATION;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; EPIGENESIS, GENETIC; ETOPOSIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; MALE; MICE, INBRED C57BL; POLYCOMB REPRESSIVE COMPLEX 2; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; PYRIDONES; RNA, MESSENGER; TIME FACTORS; TOPOISOMERASE II INHIBITORS; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84923296051     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3077     Document Type: Article

References (41)

1. Simon R and Roychowdhury S. Implementing personalized cancer genomics in clinical trials. Nature reviews Drug discovery. 2013; 12(5):358-369.
2. Yap TA, Omlin A and de Bono JS. Development of therapeutic combinations targeting major cancer signaling pathways. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013; 31(12):1592-1605.
3. Toniatti C, Jones P, Graham H, Pagliara B and Draetta G. Oncology drug discovery: planning a turnaround. Cancer discovery. 2014; 4(4):397-404.
4. Baldwin EL and Osheroff N. Etoposide, topoisomerase II and cancer. Current medicinal chemistry Anti-cancer agents. 2005; 5(4):363-372.
5. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101(25):9309-9314.
6. de Resende MF, Vieira S, Chinen LT, Chiappelli F, da Fonseca FP, Guimaraes GC, Soares FA, Neves I, Pagotty S, Pellionisz PA, Barkhordarian A, Brant X and Rocha RM. Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer. Journal of translational medicine. 2013; 11:36.
7. Murphy AJ, Hughes CA, Barrett C, Magee H, Loftus B, O'Leary JJ and Sheils O. Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival. Cancer research. 2007; 67(6):2893-2898.
8. Li X, Liu Y, Chen W, Fang Y, Xu H, Zhu HH, Chu M, Li W, Zhuang G and Gao WQ. TOP2Ahigh is the phenotype of recurrence and metastasis whereas TOP2Aneg cells represent cancer stem cells in prostate cancer. Oncotarget. 2014; 5(19):9498-9513.
9. Pienta KJ and Lehr JE. Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix. The Journal of urology. 1993; 149(6):1622-1625.
10. Millikan R and Logothetis C. Update of the NCCN guidelines for treatment of prostate cancer. Oncology. 1997; 11(11A):180-193.
11. Zhu YP, Yao XD, Zhang SL, Dai B, Zhang HL, Shen YJ, Zhu Y, Shi GH, Lin GW and Ye DW. Oral etoposide and oral prednisone for the treatment of castration resistant prostate cancer. The Kaohsiung journal of medical sciences. 2014; 30(2):82-85.
12. Buonerba C, Federico P, Bosso D, Puglia L, Policastro T, Izzo M, Perri F, Vittoria Scarpati GD, Ferro M, Cobelli OD, De Placido S, Aieta M, Imbimbo C, Longo N and Di Lorenzo G. Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients. Future oncology. 2014; 10(8):1353-1360.
13. Flechon A, Pouessel D, Ferlay C, Perol D, Beuzeboc P, Gravis G, Joly F, Oudard S, Deplanque G, Zanetta S, Fargeot P, Priou F, Droz JP and Culine S. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2011; 22(11):2476-2481.
14. Loriot Y, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Bossi A and Fizazi K. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2009; 20(4):703-708.
15. Ellis L, Lehet K, Ku S, Azabdaftari G and Pili R. Generation of a syngeneic orthotopic transplant model of prostate cancer metastasis. Oncoscience. 2014 1(10):609-613.
16. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010; 18(1):11-22.
17. Bracken AP, Dietrich N, Pasini D, Hansen KH and Helin K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes & development. 2006; 20(9):1123-1136.
18. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C and Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science signaling. 2013; 6(269):pl1.
19. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C and Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer discovery. 2012; 2(5):401-404.
20. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra A, 3rd, Diaz E, LaFrance LV, Mellinger M, Duquenne C, Tian X, Kruger RG, McHugh CF, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012; 492(7427):108-112.
21. Watson PA, Ellwood-Yen K, King JC, Wongvipat J, Lebeau MM and Sawyers CL. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. Cancer research. 2005; 65(24):11565-11571.
22. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L, Kim U, Chai LS, Kakati S, Arya SK and Sandberg AA. The LNCaP cell line--a new model for studies on human prostatic carcinoma. Progress in clinical and biological research. 1980; 37:115-132.
23. Foster BA, Gingrich JR, Kwon ED, Madias C and Greenberg NM. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer research. 1997; 57(16):3325-3330.
24. Chen T, Sun Y, Ji P, Kopetz S and Zhang W. Topoisomerase IIalpha in chromosome instability and personalized cancer therapy. Oncogene. 2014.
25. Miranda TB, Cortez CC, Yoo CB, Liang G, Abe M, Kelly TK, Marquez VE and Jones PA. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Molecular cancer therapeutics. 2009; 8(6):1579-1588.
26. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K and Sawyers CL. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107(39):16759-16765.
27. Kamradt JM and Pienta KJ. Etoposide in prostate cancer. Expert opinion on pharmacotherapy. 2000; 1(2):271-275.
28. Yang YA and Yu J. EZH2, an epigenetic driver of prostate cancer. Protein Cell. 2013; 4(5):331-341.
29. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA and Chinnaiyan AM. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002; 419(6907):624-629.
30. Wyce A, Ganji G, Smitheman KN, Chung CW, Korenchuk S, Bai Y, Barbash O, Le B, Craggs PD, McCabe MT, Kennedy-Wilson KM, Sanchez LV, Gosmini RL, Parr N, McHugh CF, Dhanak D, et al. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models. PloS one. 2013; 8(8):e72967.
31. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nature reviews Molecular cell biology. 2002; 3(6):430-440.
32. Piunti A, Rossi A, Cerutti A, Albert M, Jammula S, Scelfo A, Cedrone L, Fragola G, Olsson L, Koseki H, Testa G, Casola S, Helin K, D'Adda di Fagagna F and Pasini D. Polycomb proteins control proliferation and transformation independently of cell cycle checkpoints by regulating DNA replication. Nature communications. 2014; 5:3649.
33. Ellis L, Lehet K, Ramakrishnan S, Adelaiye R, Miles KM, Wang D, Liu S, Atadja P, Carducci MA and Pili R. Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression. PloS one. 2011; 6(11):e27178.
34. Langmead B, Trapnell C, Pop M and Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome biology. 2009; 10(3):R25.
35. Robinson MD and Oshlack A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome biology. 2010; 11(3):R25.
36. Anders S and Huber W. Differential expression analysis for sequence count data. Genome biology. 2010; 11(10):R106.
37. Huang da W, Sherman BT and Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature protocols. 2009; 4(1):44-57.
38. Chi P, Chen Y, Zhang L, Guo X, Wongvipat J, Shamu T, Fletcher JA, Dewell S, Maki RG, Zheng D, Antonescu CR, Allis CD and Sawyers CL. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature. 2010; 467(7317):849-853.
39. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome biology. 2004; 5(10):R80.
40. Smyth GK. (2005). Limma: linear models for microarray data. In: Gentleman RC, V.; Dudoit, S.; Irizarry, R.; Huber, R., ed. Bioinformatics and Computational Biology Solutions using R and Bioconductor: Springer), pp. 397-420.
41. Warnes G.R.B.L, Gentleman R., Liaw W.B.A., Lumley T., Maechler M., Magnusson A., Moeller S., Schwartz M., Venables B. . Various R programming tools for plotting data. 2014.